Cas No.: | 1011529-10-4 |
Chemical Name: | Azvudine |
Synonyms: | RO 0622 |
SMILES: | O=C1N=C(N)C=CN1[C@H]2[C@@H](F)[C@@H]([C@](CO)(N=[N+]=[N-])O2)O |
Formula: | C9H11FN6O4 |
M.Wt: | 286.223 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Publication: | 1. Klumpp K, et al. J Biol Chem. 2008 Jan 25;283(4):2167-75. |
Description: | Azvudine (RO 0622) is a potent HCV NS5B RNA polymerase inhibitor, inhibits HCV replication in the replicon system with IC50 of 24 nM; inhibits RNA synthesis by HCV polymerases from either HCV genotypes 1a and 1b or containing S96T or S282T point mutations (IC50=10-100 nM). |
In Vitro: | Azvudine displays strong inhibition on wild-type HIV-1IIIB and HIV-1RF with an EC50 ranging from 30 to 110 pM. The EC50 values of Azvudine against HIV-1KM018, HIV-1TC-1 and HIV-1WAN T69N are 6.92, 0.34 and 0.45 nM, respectively. Azvudine is sensitive to NRTIs-resistant strain HIV-174V, PIs-resistant strains HIV-1L10R/M46I/L63P/V82T/I84V and HIV-1RF V82F/184V, and FIs-resistant strain pNL4-3 gp41 (36G) V38A/N42T. The EC50 values of Azvudine against these resistant strains are 0.11, 0.14, 0.37 and 0.36 nM respectively[1]. |
References: | [1]. Wang RR, et al. Azvudine, a novel nucleoside reverse transcriptase inhibitor showed good drug combination features and better inhibition on drug-resistant strains than lamivudine in vitro. PLoS One. 2014 Aug 21;9(8):e105617. |